Amphetamine

Amphetamine

SCHEMBL4387791

CC(N)Cc1ccccc1.CCOP(=O)(O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3

The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 2/20 0.59
SLC6A3 known ✓ Q01959 1/20 0.59
SLC6A4 P31645 3/20 0.59
TAAR1 Q96RJ0 2/20 0.59
MAOA P21397 1/20 0.59
SIGMAR1 Q99720 1/20 0.59
CYP2A6 P11509 1/20 0.59
ADORA2A P29274 1/20 0.59
ADORA1 P30542 1/20 0.59
LAP3 P28838 5/20 0.53
ANPEP P15144 2/20 0.51
TSHR P16473 1/20 0.46
PIN1 Q13526 2/20 0.46
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amphetamine SCHEMBL4382899 0.85 LAP3 (0.66) SLC6A4SLC6A2TAAR1MAOASLC6A3
Dextroamphetamine SCHEMBL547496 0.85 TAAR1 (0.76) SLC6A4SLC6A2TAAR1MAOASLC6A3
Amphetamine SCHEMBL113682 0.85 TAAR1 (0.76) SLC6A4SLC6A2TAAR1MAOASLC6A3
Dextroamphetamine SCHEMBL17924971 0.83 TAAR1 (0.73) SLC6A4SLC6A2TAAR1MAOASLC6A3
Amphetamine SCHEMBL16858761 0.83 TAAR1 (0.73) SLC6A4SLC6A2TAAR1MAOASLC6A3
Levamfetamine SCHEMBL31637605 0.83 TAAR1 (0.73) SLC6A4SLC6A2TAAR1MAOASLC6A3
Methamphetamine SCHEMBL4377970 0.82 SIGMAR1 (0.62) TAAR1SIGMAR1LAP3PIN1
Methamphetamine SCHEMBL4377972 0.82 SIGMAR1 (0.62) TAAR1SIGMAR1LAP3PIN1
Amphetamine SCHEMBL4559616 0.77 TAAR1 (0.83) SLC6A4SLC6A2TAAR1MAOASLC6A3
Amphetamine SCHEMBL28990193 0.77 TAAR1 (0.91) SLC6A4SLC6A2TAAR1MAOASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121029-A2 PRODRUGS AND METHODS OF MAKING AND USING THE SAME Neurogesx, Inc. (US) 2009-11-25 EP disclosed
US-20080318905-A1 Prodrugs and methods of making and using the same NEUROGESX, INC. 2008-12-25 US disclosed
WO-2008070149-A2 PRODRUGS AND METHODS OF MAKING AND USING THE SAME NEUROGESX, INC. (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318905-A1 Prodrugs and methods of making and using the same NAPEPLD, CES2, MTAP SLC6A2 106/4885SLC6A3 153/4885SLC6A4 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.